Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose deferasirox for oxidative stress in sickle cell disease
NL-OMON20240Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of deferasirox in sickle cell disease (SCD), sponsored by Amsterdam University Medical Center. Primary endpoints: Change in Point of Sickling and Safety of deferasirox. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
deferasirox
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NL-OMON20240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20240.